ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
A periodic shareholding pattern filing for Zim Laboratories Ltd for the quarter ended March 31, 2026, disclosing promoter and public shareholding details.
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
Zim Laboratories Limited has announced the successful passing of Special Resolutions through a postal ballot, approving the remuneration structure for its Managing and Whole-Time Directors.
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.
Zim Laboratories Limited has scheduled a board meeting for August 6, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Zim Laboratories allotted 1,09,451 equity shares under its ESOP scheme. Total paid-up capital increased to 5,36,58,488 shares.
Zim Laboratories allotted 1,09,451 equity shares under its ESOP/ESPS scheme. This increased the company's paid-up share capital to Rs 53.66 Crore.
ZIM Laboratories allotted 1,09,451 ESOP shares, realizing Rs.84.71 lakh (≈0.85 Crore). The allotment increases paid-up equity capital to Rs.53.66 Crore.
ZIM Laboratories issued a Postal Ballot notice to revise remuneration for its MD and Whole-Time Director. Total proposed annual compensation for both executives is Rs. 5.5 Crore.
ZIM Laboratories issued a Postal Ballot notice for shareholder approval of revised remuneration for its Managing Director and Whole-Time Director. Remote e-voting runs from July 13 to August 11.